SCHEMBL31426239

SCHEMBL31426239

OCc1cccc2c(F)coc12

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.37
PSMB5 P28074 2/20 0.33
PSMB8 P28062 1/20 0.33
APOBEC3G Q9HC16 1/20 0.32
PDCD1 Q15116 1/20 0.32
CD274 Q9NZQ7 1/20 0.32
MEN1 O00255 2/20 0.31
KMT2A Q03164 2/20 0.31
SLC11A2 P49281 1/20 0.31
GPR84 Q9NQS5 1/20 0.31
RAB9A P51151 1/20 0.31
IDO1 P14902 1/20 0.31
KDM4E B2RXH2 1/20 0.30
LMNA P02545 1/20 0.30
TP53 P04637 1/20 0.30
MAPT P10636 1/20 0.30
TSHR P16473 1/20 0.30
ALOX12 P18054 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25112508 0.83 MAOB (0.37) MAOBIDO1
SCHEMBL25004730 0.83 GABRA1 (0.42) PSMB5PSMB8KMT2ALMNAMAPT
SCHEMBL25248388 0.81 TAAR1 (0.47) MAPT
Hydrochloric Acid SCHEMBL25390767 0.80 TAAR1 (0.46) MAOBIDO1MAPT
SCHEMBL11702360 0.78 SMN1; SMN2 (0.41) MAOBPDCD1CD274MEN1KMT2A
SCHEMBL23218984 0.77 MAOB (0.37) MAOBAPOBEC3GPDCD1CD274SLC11A2
SCHEMBL11705295 0.74 PDCD1 (0.49) MAOBPDCD1CD274MEN1KMT2A
SCHEMBL24947654 0.73 GYS1 (0.30) MAOB
SCHEMBL31426265 0.73 BACE1 (0.36) IDO1
SCHEMBL25019378 0.72 GSK3B (0.30)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250114345-A1 COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF ONCOPIA THERAPEUTICS, INC. D/B/A/ SK LIFE SCIENCE LABS 2025-04-10 US disclosed
WO-2025049994-A1 COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF ONCOPIA THERAPEUTICS, INC. D/B/A SK LIFE SCIENCE LABS (US) 2025-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250114345-A1 COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF EP300, CREBBP, HDAC1 MAOB 1998/4885PSMB5 168/4885PSMB8 267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.